Dietary changes to prevent glucose problems in adults with cystic fibrosis
Official title: A Dietary Intervention to Improve Glucose Tolerance in Adults with Cystic Fibrosis
Funded at Emory University · NIH-11378277 · Data updated 2026-11-12
A nutrition-focused study in adults with cystic fibrosis will test how eating quality sugars affects the development of glucose intolerance and CFRD.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | September 15, 2022 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $662,204 |
| NIH project number | 5R01DK133523-05 |
| Project ID | NIH-11378277 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with cystic fibrosis who are at risk for glucose intolerance or CFRD.
✕Less likely to help
CF patients not able to participate due to medical contraindications or unable to comply with dietary interventions.
What this research studies
This project will enroll adults with CF to explore whether reducing added sugars and adjusting carbohydrate quality improves how the body handles glucose. Researchers will compare different dietary patterns over time and measure glucose tolerance, insulin responses, and overall health. The study builds on CF care by examining if diet quality—not just calories—can influence CFRD risk. Participants will receive personalized dietary guidance and ongoing monitoring through clinic visits and lab tests. Findings could shape evidence-based dietary recommendations for CF patients.
Why it matters
Potential benefit: If successful, the study could lead to clearer dietary guidance that helps prevent CFRD and supports better long-term health for adults with CF.
How similar studies have gone: Previous research suggests diet quality may impact glucose metabolism, but this study tests a specific CF-focused dietary approach.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Alvarez, Jessica Alejandra — Emory University
- Study coordinator: Alvarez, Jessica Alejandra
Related research
Other NIH-funded projects on the same topics.
-
Blocking CFTR in the cervix to prevent conception without hormones
A non-hormonal approach aims to stop sperm from entering the uterus by making cervical mucus too thick for sperm, potentially offering a new contraception option.
-
Optimizing Treatments for People with Cystic Fibrosis on Highly Effective Modulator Therapy
A real-world study in people with cystic fibrosis on highly effective CFTR modulator therapy to understand how traditional CF treatments can be adjusted safely.
-
Elastin-like particles to deliver gene therapies for cystic fibrosis
A new nanoparticle system is being developed to deliver genetic therapies directly to the lungs of people with cystic fibrosis, including those with nonsense mutations.
-
Pharmacogenomic Predictors of Clinical Responses in Cystic Fibrosis using Targeted WGS
A study looking at how genetic information from whole-genome sequencing can predict how people with cystic fibrosis respond to medications, using a focused set of pharmacogenomic genes.
-
Ceftaroline-meropenem combo to beat MRSA in cystic fibrosis
A new combination antibiotic approach is being tested to help people with cystic fibrosis who have MRSA infections that resist standard treatments.
-
Gut microbiome in cystic fibrosis and colorectal cancer risk
Researchers are studying how the gut bacteria in adults with cystic fibrosis influence the development of colorectal cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.